Media Requests
Please send all media-related inquiries and interview requests to mediarelations@lls.org.
An LLS representative will respond as soon as possible.
SUBARU OF AMERICA DEDICATES JUNE TO SHARING HOPE AND WARMTH WITH THOSE BATTLING CANCER
CAMDEN, N.J. – June 1, 2021 – Subaru of America, Inc. today announced that it will continue its longtime partnership with The Leukemia & Lymphoma Society (LLS) for the sixth consecutive year to send love, hope and warmth to patients battling cancer during Subaru Loves to Care month in June. As part of the partnership, the automaker and a record 606 participating Subaru retailers nationwide will suppo...
The Leukemia & Lymphoma Society Launches IMPACT Research Grants to Help Underserved Patients Access Clinical Trials
Collaborations with Mayo Clinic, Vanderbilt University Medical Center and Weill Cornell Medicine will Increase Representation of Geographically, Ethnically and Economically Underserved Communities in Clinical Trials RYE BROOK, N.Y., May 6, 2021 – The Leukemia & Lymphoma Society (LLS) announced today the launch of the IMPACT (Influential Medicine Providing Access to Clinical Trials) research grants to in...
FDA APPROVES NEW TREATMENT OPTION FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
The U.S. Food and Drug Administration (FDA) approved loncastuximab tesirine-lpyl (ZYNLONTA) to treat adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more earlier treatments with systemic therapy including diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma. The FDA approval is based on a Phase 2 study that enrolled 145 patients with R/R DLBCL or high-grade...
COVID-19 VACCINE SAFETY AMONG BLOOD CANCER PATIENTS
Background and Purpose Because of the health emergency created by the COVID-19 virus, three COVID-19 vaccinations have been authorized by the U.S. FDA for Emergency Use Administration (EUA). The vaccine clinical trials were streamlined and essentially excluded people with a current or past diagnosis of cancer. Therefore, how people with blood cancer respond to the COVID-19 vaccinations is unknown. The Leukemia ...
LLS TAP Announces Five New Investments Supporting Next Generation Immunotherapies
RYE BROOK, N.Y., April 22, 2021 /PRNewswire/ -- The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) today announced five new investments aimed at speeding the development of new and improved immunotherapies for the treatment of blood cancers. LLS has dedicated more than $100 million over the past several decades, through both grants and TAP investments, to advancing p...
LLS Statement on Racial Justice in Light of Derek Chauvin Verdict
As a leading patient focused organization dedicated to saving lives, we watched in horror the images of George Floyd’s senseless killing last summer and the continued cycle of racial violence and injustice that has followed. We are hopeful that today’s verdict is a first of many steps toward greater justice and equity for Black people and people of color. It is important to acknowledge and recognize th...
Thousands Nationwide Reimagine Iconic Stair Climb to Take Down Cancer
View full multimedia release here. Rye Brook, NY (April 21, 2021) – Thousands across the nation are stepping up to help defeat an adversary that has long plagued Americans — cancer. On May 15, The Leukemia & Lymphoma Society (LLS) will host its trailblazing event, Big Climb, from coast to coast. Participants will virtually climb up the Columbia Center’s 61 stories in Seattle, WA, where the event...
Statement on Recent mRNA-based COVID-19 Vaccines Studies for Blood Cancer Patients
The Leukemia & Lymphoma Society (LLS) has heard from blood cancer patients and caregivers who are concerned about new research suggesting that mRNA-based COVID-19 vaccines may offer less protection for people with certain blood cancers. The findings from the new research confirm what LLS and other experts expected: that certain types of blood cancer and blood cancer treatments could affect vaccine response. Ad...